Bush's precautionary principle

Biotech companies have no choice but to fight the Bush administration's move to ban therapeutic cloning research, and only partially because the technology holds potential to provide important medical advances in the treatment of diabetes, neurological disorders such as Parkinson's disease and cardiovascular disease.

The White House policy represents a dangerous step toward the erosion of rational regulation of science, and thus the implications of the logic employed by Bush and other supporters of the Weldon/Brownback legislation in Congress are more worrying than the proposed ban itself.